First Tracks Biotherapeutics Stock Gains After Guggenheim Initiates Coverage With $100 Target

Shares of First Tracks Biotherapeutics Inc. (NASDAQ:TRAX) gained 3.8% in Wednesday trading after Guggenheim initiated coverage on the company with a Buy rating and a price target of $100.

Guggenheim's Bullish Thesis

In a note to clients, Guggenheim analyst Yatin Suneja expressed confidence in the company's lead asset, ANB033, and its target, anti-CD122. The firm highlighted the drug's potential across a range of autoimmune diseases.

Suneja noted that the CD122/IL-15 signaling pathway is one of the few underdeveloped targets in the autoimmunity space. According to Guggenheim, early clinical success for First Tracks' candidate in indications such as Celiac Disease, Eosinophilic Esophagitis, and Vitiligo suggests a widening therapeutic application.

Market and Scientific Context

Ad

The analyst's report emphasized that First Tracks is the only publicly traded small-to-mid-cap company currently developing an anti-CD122 monoclonal antibody. This positions the company uniquely in a competitive field.

CD122, also known as IL-2Rβ/IL-15Rβ, is a receptor subunit involved in both IL-2 and IL-15 signaling. Genetic links have implicated this pathway in several autoimmune conditions, including:

• Celiac Disease
• Alopecia Areata
• Type 1 Diabetes
• Atopic Dermatitis

Guggenheim identified four major players with programs targeting the broader IL-15 and CD122 space, including two with IL-15 monoclonal antibodies and two, including First Tracks, with anti-CD122 monoclonal antibodies.